Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494766 · ClinicalTrials.gov registry record · NA
Efficacy of Tyrosine in Restless Legs Syndrome
A NA study, sponsored by Seton Healthcare Family.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT01494766 is a NA study that has completed, run by Seton Healthcare Family. The registered enrollment target is 5 participants.
The verdict
NCT01494766, a NA study, has completed, sponsored by Seton Healthcare Family.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS). Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms. No studies to date have been done to determine the role of tyrosine in RLS. This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient. In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS. Patients' symptoms will be monitored on a weekly basis for six weeks.
Interventions
- DIETARY_SUPPLEMENT L-Tyrosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494766
The ClinicalTrials.gov registry entry for NCT01494766 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seton Healthcare Family, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-Tyrosine is the first listed.
NCT01494766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494766 about?
NCT01494766 is a clinical study titled "Efficacy of Tyrosine in Restless Legs Syndrome". Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restles...
What is the current status of trial NCT01494766?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2012-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01494766?
The interventions under investigation include: L-Tyrosine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01494766?
This trial is sponsored by Seton Healthcare Family, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.